J Korean Diabetes.  2016 Mar;17(1):11-16. 10.4093/jkd.2016.17.1.11.

Hypoglycemia and Health Costs

• Lee YH
• Kim G
• Kang ES

• KMID: 2161125
• DOI: http://doi.org/10.4093/jkd.2016.17.1.11

Abstract

Diabetes is one of the most common and rapidly increasing chronic metabolic disorders in the world. It causes serious complications and mortality, with a large burden to the public health care system and to individual patients. Hypoglycemia is an acute complication of diabetes that increases morbidity, mortality, and economic costs. It remains a major limiting factor in the attainment of optimal glycemic control in patients with diabetes. Medical expenditures for potentially preventable severe hypoglycemia are substantial, with the highest proportion of direct medical costs resulting from a relatively small number of patients. Severe hypoglycemia, which is generally associated with insulin or sulfonylurea therapy, can be serious, and hospitalization has been a major driver of increasing healthcare resource use and costs. Patients with increased numbers of non-severe hypoglycemia events are at risk for long-term complications and mortality, reductions in quality of life, increased fear and anxiety, reduced work productivity, and increased healthcare costs. Although the prevalence and incidence of hypoglycemia in diabetes are rapidly increasing in Korea, the economic consequences of hypoglycemia remain unclear.

Keyword

Diabetes mellitus; Health care costs; Hypoglycemia

MeSH Terms

Anxiety
Delivery of Health Care
Diabetes Mellitus
Efficiency
Health Care Costs*
Health Expenditures
Hospitalization
Humans
Hypoglycemia*
Incidence
Insulin
Korea
Mortality
Prevalence
Public Health
Quality of Life
Insulin

Reference

References

1. Ha KH, Kim DJ. Trends in the diabetes epidemic in Korea. Endocrinol Metab (Seoul). 2015; 30:142–6.

2. Korean Diabetes Association. Korean Diabetes Fact Sheet 2013. Seoul: Korean Diabetes Association;2013.

3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837–53.

4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359:1577–89.

5. Korean Diabetes Association. Korean Diabetes Fact Sheet 2015. Seoul: Korean Diabetes Association;2015.

6. Kim JT, Oh TJ, Lee YA, Bae JH, Kim HJ, Jung HS, Cho YM, Park KS, Lim S, Jang HC, Lee HK. Increasing trend in the number of severe hypoglycemia patients in Korea. Diabetes Metab J. 2011; 35:166–72.

7. Holstein A, Plaschke A, Egberts EH. Clinical characterisation of severe hypoglycaemia: a prospective population-based study. Exp Clin Endocrinol Diabetes. 2003; 111:364–9.

8. Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W, Frier BM, Morris AD. DARTS/MEMO Collaboration. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care. 2003; 26:1176–80.

9. Chan SP, Ji LN, Nitiyanant W, Baik SH, Sheu WH. Hypoglycemic symptoms in patients with type 2 diabetes in Asia-Pacific-Real-life effectiveness and care patterns of diabetes management: the RECAP-DM study. Diabetes Res Clin Pract. 2010; 89:e30–2.

10. Lee SA, Cho SJ, Jeong MH, Kim YJ, Kim CJ, Cho MC, Kim HS, Ahn Y, Koh G, Lee JM, Oh SK, Yun KH, Kim HY, Cho CG, Lee DH. KAMIR/KorMI Registry. Hypoglycemia at admission in patients with acute myocardial infarction predicts a higher 30-day mortality in patients with poorly controlled type 2 diabetes than in well-controlled patients. Diabetes Care. 2014; 37:2366–73.

11. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, MacMahon S, Grobbee DE, Kengne AP, Marre M, Heller S. ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010; 363:1410–8.

12. Mellbin LG, Malmberg K, Rydén L, Wedel H, Vestberg D, Lind M. The relationship between glycaemic variability and cardiovascular complications in patients with acute myocardial infarction and type 2 diabetes: a report from the DIGAMI 2 trial. Eur Heart J. 2013; 34:374–9.

13. Park HK. Severe Hypoglycemia and cardiovascular disease in type 2 diabetes. Diabetes Metab J. 2015; 39:478–80.

14. Cox DJ, Penberthy JK, Zrebiec J, Weinger K, Aikens JE, Frier B, Stetson B, DeGroot M, Trief P, Schaechinger H, Hermanns N, Gonder-Frederick L, Clarke W. Diabetes and driving mishaps: frequency and correlations from a multinational survey. Diabetes Care. 2003; 26:2329–34.

15. Quilliam BJ, Simeone JC, Ozbay AB, Kogut SJ. The incidence and costs of hypoglycemia in type 2 diabetes. Am J Manag Care. 2011; 17:673–80.

16. Jönsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with Type 2 diabetes in Sweden. Value Health. 2006; 9:193–8.

17. Kim Y, Shin S, Park J, Jung Y, Kim J, Lee TJ, Bae EY, Song HJ. Coating methods in healthcare. Seoul: National Evidance-based Healthcare Collaborationg Agency;2013.

18. Reviriego J, Gomis R, Marañés JP, Ricart W, Hudson P, Sacristán JA. Cost of severe hypoglycaemia in patients with type 1 diabetes in Spain and the cost-effectiveness of insulin lispro compared with regular human insulin in preventing severe hypoglycaemia. Int J Clin Pract. 2008; 62:1026–32.

19. Rhoads GG, Orsini LS, Crown W, Wang S, Getahun D, Zhang Q. Contribution of hypoglycemia to medical care expenditures and short-term disability in employees with diabetes. J Occup Environ Med. 2005; 47:447–52.

20. Ha WC, Oh SJ, Kim JH, Lee JM, Chang SA, Sohn TS, Son HS. Severe hypoglycemia is a serious complication and becoming an economic burden in diabetes. Diabetes Metab J. 2012; 36:280–4.

21. Kim G, Lee YH, Han MH, Lee EK, Kim CH, Kwon HS, Jeong IK, Kang ES, Kim DJ. Economic burden of hypoglycemia in patients with type 2 diabetes mellitus from Korea. PLoS One. 2016; 11:e0151282.

22. Hwang JA, Park TC, Jung SH, Kim HJ, Kim DJ, Kim SH, Nam MK, Kim TH, Lee MK, Lee KW. Direct medical costs of type 2 diabetic patients in the tertary hospital. Korean Diabetes J. 2008; 32:259–68.

23. Yong YM, Shin KM, Lee KM, Cho JY, Ko SH, Yoon MH, Kim TW, Jeong JH, Park YM, Ko SH, Ahn YB. Intensive individualized reinforcement education is important for the prevention of hypoglycemia in patients with type 2 diabetes. Diabetes Metab J. 2015; 39:154–63.